Completed PHASE3 INTERVENTIONAL 2-arm NCT00216619

The Prolonged Use of Topiramate for Preventing Migraine Headaches (PROMPT)

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention

Sponsor: Janssen Pharmaceutica N.V., Belgium

Conditions Migraine

Interventions Topiramate Topiramate - Placebo

Updated 6 times since 2017 Last updated: Jul 1, 2014 Started: Nov 30, 2003 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Migraine, this trial is completed. The trial is conducted by Janssen Pharmaceutica N.V., Belgium and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutica N.V., Belgium

Data source: Janssen Pharmaceutica N.V., Belgium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aabenraa, Denmark , Antwerp, Belgium , Athens, Greece , Berlin, Germany , Biel/Bienne, Switzerland , Bodø, Norway , Brighton, United Kingdom , Budapest, Hungary , Budapest Na, Hungary , Bursa, Turkey (Türkiye) and 58 more locations